VVOS — Vivos Therapeutics, Inc.

Vivos (VVOS) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Full-year revenue increased by 16% to $17 million, driven by a $4.8 million rise in sleep testing services and $2.2 million from treatment at the Sleep Center of Nevada (SCN). However, this was partially offset by a $1.4 million decline in product revenue from legacy VIP dentists and a $2 million drop in VIP enrollment revenue.
• Gross Profit: Increased to $10.5 million (60% gross margin), up from $9 million in 2024.
• Operating Expenses: Rose significantly to $30.4 million from $20.2 million, primarily due to increased general and administrative costs associated with the SCN acquisition.
• Net Loss: Increased to $21.2 million, reflecting higher costs from the strategic transition.
• Cash Position: As of December 31, 2025, Vivos had $2 million in cash and total liabilities of $26.7 million, up from $7.3 million in 2024.

2. Strategic Updates and Business Highlights

• Vivos completed the acquisition of SCN in June 2025, marking a pivotal shift towards a medical provider-focused business model.
• The company has received in-network status with several commercial health insurance payers, enhancing patient access to treatments.
• The introduction of Sleep Optimization (SO) teams aims to improve patient education and treatment uptake.
• Vivos plans to expand its diagnostic and treatment services, including a pediatric OSA program and collaborations with specialty medical groups.

3. Forward Guidance and Outlook

• Vivos anticipates stronger revenue growth in 2026, driven by increased patient demand and the successful integration of SCN.
• The company aims to achieve cash flow positive operations by the end of 2026, requiring a revenue run rate close to double that of 2025.
• Continued expansion of the SO teams and further insurance participation are expected to bolster revenue.

4. Bad News, Challenges, or Points of Concern

• Q4 Revenue Decline: Revenue dropped to $3.8 million in Q4 from $6.8 million in Q3, attributed to provider absences and challenges in maintaining sufficient staffing levels.
• Increased Costs: Significant one-time expenses related to the SCN acquisition and integration have contributed to the net loss.
• Provider Recruitment Issues: The company faced unexpected provider attrition in Q4, impacting service delivery and revenue generation. Although recruitment efforts are underway, this remains a concern for operational stability.

5. Notable Q&A Insights

• Q4 Performance Explanation: CEO Kirk Huntsman explained that the decline in Q4 revenue was due to unforeseen provider absences, which have since been addressed with additional recruitment.
• Future Revenue Expectations: Huntsman indicated that Q1 2026 is expected to show improvement, with more significant gains anticipated in Q2 as new providers become fully operational and in-network insurance coverage begins to impact revenue.
• Long-Term Growth Strategy: The company is optimistic about its new affiliation model, which is more capital-efficient than acquisitions, allowing for rapid expansion across various markets.
• Patient Demand: There is strong interest from specialty medical groups in Vivos' treatments, indicating a growing market for their services.

Overall, while Vivos is navigating challenges related to staffing and integration, the strategic pivot towards a medical provider-focused model and the acquisition of SCN are seen as significant steps towards future growth and profitability.